Haploid genetic screen to identify host genes required for RNA virruses
单倍体遗传筛选以确定 RNA 病毒所需的宿主基因
基本信息
- 批准号:8643866
- 负责人:
- 金额:$ 41.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-04-10 至 2019-03-31
- 项目状态:已结题
- 来源:
- 关键词:AllelesAnimal ModelAntiviral AgentsCandidate Disease GeneCellsCessation of lifeClinicCoupledDevelopmentDiseaseDrug TargetingDrug resistanceEbola virusEffectivenessEncephalitis VirusesFilovirusGenesGenetic ScreeningGenetic screening methodGenomeHaploidyHepatitis A VirusHepatitis C virusHumanHuman Cell LineHuman GenomeInfectionInfluenzaInfluenza A virusKnock-outLeadLibrariesMessenger RNAMutationPharmaceutical PreparationsProteinsRNARNA InterferenceRNA VirusesResistance developmentSeriesTechniquesTherapeuticTherapeutic InterventionToxic effectVenezuelan Equine Encephalitis VirusViralViral ProteinsVirusWest Nile virusYellow fever virusbasecomparativecomparative efficacydeep sequencinginhibitor/antagonistinnovationpandemic diseasepathogenreceptorresistant strainsmall moleculetissue culturetool
项目摘要
RNA viruses replicate with extremely high mutation rates allowing them to quickly develop resistance to conventional drugs that directly target viral proteins. Viruses critically rely on cellular genes for their replication and spread. Therefore, using these host genes as drug targets could create a much higher barrier to the development of drug resistance. To identify host genes critical to infection of a wide range of different emerging or reemerging RNA viruses, we will use an innovative method for genetic screens in human cells. This approach is based on unique haploid or near-haploid human cell lines in which it is possible to create knockout alleles en masse creating a library of cells with mutations in essentially all genes. Coupled with deep sequencing this allows us to screen the human genome for genes that are critical for viral replication. We have applied this technique to identify entry factors required for Ebola virus and found that NPC1 is the intracellular receptor for different filoviruses. Here we propose to perform a series of comparative genetic screens for host genes required for a compendium of RNA viruses including different strains of influenza A virus, Venezuelan equine encephalitis virus. La Crosse encephalitis virus, yellow fever virus, West Nile virus, hepatitis A virus and hepatitis C virus. These screens will generate candidate genes that need to be rigorously validated in relevant tissue culture and animal models. For this we will develop AAV-shRNAs- RNAi tools. These will be used to: 1) validate host cell candidate genes identified and deemed important for the replication of viral pathogens; 2) compare efficacy of host target knockdown with direct targeting of viral mRNAs with host candidate genes; 3) identify the toxicity of small molecule inhibitors directly related to direct knockdown of the candidate protein from toxicity related to pleiotropic effects of the small molecule inhibitors.
RNA病毒以极高的突变率复制,使它们能够迅速对直接靶向病毒蛋白的常规药物产生耐药性。病毒严重依赖细胞基因进行复制和传播。因此,使用这些宿主基因作为药物靶标可以为耐药性的发展创造更高的屏障。为了鉴定对感染各种不同的新出现或重新出现的RNA病毒至关重要的宿主基因,我们将使用一种创新的方法在人类细胞中进行遗传筛选。该方法基于独特的单倍体或近单倍体人类细胞系,其中可以创建敲除等位基因,从而创建基本上所有基因都具有突变的细胞文库。再加上深度测序,这使我们能够筛选人类基因组中对病毒复制至关重要的基因。我们已经应用这种技术来识别埃博拉病毒所需的进入因子,并发现NPC 1是不同丝状病毒的细胞内受体。在这里,我们建议进行一系列的比较遗传筛选所需的宿主基因的RNA病毒,包括不同株的流感病毒A,委内瑞拉马脑炎病毒的纲要。拉克罗斯脑炎病毒、黄热病病毒、西尼罗河病毒、甲型肝炎病毒和丙型肝炎病毒。这些筛选将产生候选基因,需要在相关组织培养和动物模型中进行严格验证。为此,我们将开发AAV-shRNA- RNAi工具。这些将用于:1)验证所鉴定的并被认为对病毒病原体的复制重要的宿主细胞候选基因; 2)比较宿主靶标敲低与用宿主候选基因直接靶向病毒mRNA的功效; 3)从与小分子抑制剂的多效性效应相关的毒性中鉴定与候选蛋白质的直接敲低直接相关的小分子抑制剂的毒性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY S GLENN其他文献
JEFFREY S GLENN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY S GLENN', 18)}}的其他基金
Oral small molecule inhibitors of NSP4-mediated membrane-associated RNA replication of SARS-CoV-2 and other RNA viruses
NSP4 介导的 SARS-CoV-2 和其他 RNA 病毒膜相关 RNA 复制的口服小分子抑制剂
- 批准号:
10514275 - 财政年份:2022
- 资助金额:
$ 41.23万 - 项目类别:
Development of outpatient antiviral cocktails against SARS-CoV-2 and other potential pandemic RNA viruses.
开发针对 SARS-CoV-2 和其他潜在大流行性 RNA 病毒的门诊抗病毒鸡尾酒。
- 批准号:
10514264 - 财政年份:2022
- 资助金额:
$ 41.23万 - 项目类别:
Programmable antivirals: Targeting viral RNA secondary structures with LNAs and small molecules
可编程抗病毒药物:利用 LNA 和小分子靶向病毒 RNA 二级结构
- 批准号:
10514269 - 财政年份:2022
- 资助金额:
$ 41.23万 - 项目类别:
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm
优化 SARS-CoV-2 复制和相关细胞因子风暴的小分子抑制剂
- 批准号:
10681264 - 财政年份:2021
- 资助金额:
$ 41.23万 - 项目类别:
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm
优化 SARS-CoV-2 复制和相关细胞因子风暴的小分子抑制剂
- 批准号:
10470714 - 财政年份:2021
- 资助金额:
$ 41.23万 - 项目类别:
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm
优化 SARS-CoV-2 复制和相关细胞因子风暴的小分子抑制剂
- 批准号:
10187861 - 财政年份:2021
- 资助金额:
$ 41.23万 - 项目类别:
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
将广谱抗甲型流感病毒 RNA 包装抑制剂推进 IND
- 批准号:
10165884 - 财政年份:2020
- 资助金额:
$ 41.23万 - 项目类别:
Rapid development of SARS-CoV-2 specific therapeutics that leverage virus specific RNA elements
利用病毒特异性 RNA 元件快速开发 SARS-CoV-2 特异性疗法
- 批准号:
10115505 - 财政年份:2020
- 资助金额:
$ 41.23万 - 项目类别:
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
将广谱抗甲型流感病毒 RNA 包装抑制剂推进 IND
- 批准号:
9750617 - 财政年份:2017
- 资助金额:
$ 41.23万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 41.23万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 41.23万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 41.23万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 41.23万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 41.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 41.23万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 41.23万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 41.23万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 41.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 41.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists